妊娠期口服糖皮质激素与早产风险
该研究基于MotherToBaby妊娠研究(2003-2014)中528例类风湿关节炎孕妇,评估妊娠早期和晚期口服糖皮质激素剂量与早产风险的关系。结果显示,妊娠早期高和中等累积剂量及妊娠晚期每日≥10 mg泼尼松等效剂量与早产风险增加相关,而DMARDs与早产无关。
要点
- 妊娠早期高累积OCS剂量与早产风险显著增加相关(aRR 4.77)。
- 妊娠晚期每日≥10 mg泼尼松等效剂量与早产风险增加相关(aHR 2.45)。
- 生物制剂和非生物制剂DMARDs均未显示与早产风险相关。
核心结论
- 在RA孕妇中,妊娠早期和晚期较高的口服糖皮质激素剂量与早产风险增加相关。
研究设计与样本
- 基于MotherToBaby妊娠研究(2003-2014)的前瞻性队列分析,纳入528例RA孕妇,通过电话访谈和病历收集信息。
主要发现
- 总体早产风险为15.5%。
- 妊娠前139天高累积OCS剂量轨迹与无OCS相比,早产风险aRR为4.77(95% CI: 2.76, 8.26)。
- 妊娠前139天中等累积OCS剂量轨迹与无OCS相比,早产风险aRR为1.81(95% CI: 1.10, 2.97)。
- 妊娠第139天后每日≥10 mg泼尼松等效剂量与无OCS相比,早产风险aHR为2.45(95% CI: 1.32, 4.56)。
- 生物制剂DMARDs的aHR为1.08(95% CI: 0.70, 1.66),非生物制剂DMARDs的aHR为0.87(95% CI: 0.55, 1.38)。
临床怎么用
- 对于RA孕妇,应谨慎评估口服糖皮质激素的累积剂量和每日剂量,尤其是高剂量和妊娠晚期≥10 mg/日的暴露,以降低早产风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the associations between oral corticosteroid (OCS) dose early and late in pregnancy and preterm birth (PTB) among women with RA. METHODS: Pregnant women in the MotherToBaby Pregnancy Studies (2003-2014) with RA (n = 528) were included in the primary analysis. Information was collected by phone interview and from medical records. We estimated risk ratios (RR) for OCS dose trajectories and other disease-related medications before gestational day 140 and hazard ratios (HR) for time-varying exposures after gestational day 139. RESULTS: PTB risk was 15.5% overall. Compared with no OCS, PTB risk was increased in high (adjusted (a)RR: 4.77 (95% CI: 2.76, 8.26)) and medium (aRR: 1.81 (95% CI: 1.10, 2.97)) cumulative OCS dose trajectories during the first 139 gestational days. The low cumulative trajectory group was associated with an increased risk of PTB that was not statistically significant (aRR: 1.38 (95% CI: 0.79, 2.38)), and DMARDs were not associated with PTB (biologic DMARDs aHR: 1.08 (95% CI: 0.70, 1.66); non-biologic DMARDs aHR: 0.87 (95% CI: 0.55, 1.38)). OCS exposure to ⩾10 mg of prednisone equivalent daily dose after gestational day 139 vs none was associated with increased PTB rate (aHR: 2.45 (95% CI: 1.32, 4.56)), whereas <10 mg was associated with a modestly increased rate of PTB that was not statistically significant (aHR: 1.18 (95% CI: 0.60, 2.30)). CONCLUSION: Higher OCS doses vs no OCS use, both earlier and later in pregnancy, were associated with an increase in PTB among women with RA.
引用
- Palmsten K, Bandoli G, Vazquez-Benitez G, et al. Oral corticosteroid use during pregnancy and risk of preterm birth. Rheumatology (Oxford). 2020. PMID: 31566229. doi:10.1093/rheumatology/kez405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。